Does Bavarian have a blockbuster in the making?
Industry analysts see great potential in Bavarian Nordic’s cancer vaccine CV-301, which has been passing under the public radar compared with the group’s other cancer vaccine, Prostvac. The blockbuster potential is there for CV-301, but several factors have to come together before the Danish biotech can land a partnership deal.
by Benjamin Werner Christensen
While prostate cancer vaccine Prostvac has drawn most of the headlines for Bavarian Nordic for a number of years, the Danish biotech has been sitting on another candidate drug with blockbuster potential, cancer vaccine CV-301. One of the factors attesting to its potential is that CV-301 is likely to get more shots, as it were, than Prostvac.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Nordea sees strong Danish biotech sector
For abonnenter
Bavarian looking for partnerships for cancer vaccine
For abonnenter
Bavarian CEO: Better production led to first-ever profit
For abonnenter
